Ongoing Clinical Trials for Marginal Zone Lymphoma Refractory
This article presents information about 2 ongoing clinical trials for patients with marginal zone lymphoma that has not responded to treatment or has returned after previous therapy. These studies are testing new treatment combinations to help patients whose cancer has become resistant to standard approaches.
Clinical trial locations
- Belgium
- France
- Germany
- Italy
- Poland
- Portugal
Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma
This trial is designed for adults diagnosed with marginal zone lymphoma, a type of cancer affecting certain white blood cells. To participate, patients must be at least 18 years old and have received between one and three previous treatments, with at least one targeting CD20, a protein found on the surface of some cancer cells. The disease must be measurable on scans, meaning lymph nodes should be at least 15 mm in size or the spleen larger than 13 cm. Participants need to have adequate blood cell counts, normal liver and kidney function, and must be able to follow study procedures. Women of childbearing potential and men with partners who could become pregnant must use effective birth control throughout the study.
Patients cannot join the study if they have a different type of cancer, are pregnant or breastfeeding, have serious health conditions that could interfere with the trial, have participated in another clinical trial recently, or have allergies to the study medications. Those unable to provide consent or follow study instructions are also excluded.
The main goal of this trial is to compare a new treatment combination of mosunetuzumab and lenalidomide with other treatments chosen by doctors. Mosunetuzumab is a type of medicine called a monoclonal antibody that helps the immune system find and destroy cancer cells. It is given as an injection under the skin. Lenalidomide works by boosting the immune response and stopping cancer cells from growing, and is taken orally. The study aims to evaluate whether this combination can help patients live longer without their cancer getting worse.
Participants will be randomly assigned to receive either the mosunetuzumab and lenalidomide combination or a treatment selected by their doctor, which may include medications like rituximab, bendamustine, or other chemotherapy drugs. Throughout the study, patients will have regular check-ups including physical examinations, blood tests, and imaging scans to monitor the treatment’s effectiveness and any side effects.
Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies
This trial is testing treatment combinations for patients with B-cell malignancies, a group of blood cancers that develop from abnormal B lymphocytes. These are white blood cells that normally help fight infections. To be eligible, participants must be at least 18 years old and have a confirmed diagnosis of B-cell cancer that has either returned after treatment or did not respond to previous therapy. The disease must be measurable according to study guidelines. Patients need to have good physical function, meaning they can perform daily activities with minimal limitations, and must have adequate organ function. Women who can become pregnant must have a negative pregnancy test before starting treatment, and both men and women must use effective birth control during the study.
Patients are excluded if they have active cancer involvement in the central nervous system, uncontrolled infections, serious heart problems, severe kidney or liver problems, or are pregnant or breastfeeding. Those with a history of other cancers within the past three years, HIV infection, active hepatitis B or C, or who have had major surgery within four weeks before the study cannot participate. Mental conditions that could interfere with study participation or serious medical conditions that could make participation unsafe also exclude patients from the trial.
The trial is studying BGB-16673, an experimental medication known as a BTK-degrader. This drug works by breaking down a specific protein called BTK that is important in B-cell cancers. BGB-16673 is given as tablets taken by mouth. The trial will test this medication in combination with other treatments including zanubrutinib, sonrotoclax, mosunetuzumab, obinutuzumab, and glofitamab. Some of these additional medications are given through intravenous infusion directly into a vein, while others are taken as oral capsules or given as injections under the skin.
The study is conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause. Throughout the trial, doctors will regularly check patients’ health status, monitor for side effects, and assess how well the treatment is working through blood tests and medical examinations. After completing treatment, patients will need to continue using birth control for a specified period depending on which medications they received.
Summary
Currently, there are two ongoing clinical trials available for patients with marginal zone lymphoma that has not responded to treatment or has returned after previous therapy. These trials are being conducted across six European countries: Belgium, France, Germany, Italy, Poland, and Portugal. Germany and Italy are hosting both trials, offering patients in these countries more options for participation.
Both studies focus on innovative treatment approaches using medications that work with the immune system to fight cancer. The first trial specifically targets marginal zone lymphoma and compares the combination of mosunetuzumab and lenalidomide against standard treatment options. The second trial studies BGB-16673, a newer type of medication, in combination with various other drugs for B-cell malignancies, which includes marginal zone lymphoma as part of a broader group of blood cancers.
These trials represent important research efforts to find more effective treatment options for patients whose cancer has become resistant to standard therapies. Patients interested in participating should discuss these opportunities with their doctors to determine if they meet the eligibility criteria and whether participation would be appropriate for their individual situation.
